reports
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Patrick Steiner
APAML APERAM SA
ACN ACCENTURE PLC CLASS A
EXE EXEL INDUSTRIES SA
INF INFOTEL SA
EVN EVN AG
SWP SWORD GROUP SE
AUB AUBAY SA
ATE ALTEN SA
COTN COMET HOLDING AG
CAP CAPGEMINI SE
TXGN TX GROUP AG
DEZ DEUTZ AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
CIE CIE AUTOMOTIVE S.A.
LFDE LA FRANCAISE DE L'ENERGIE SA
IDR INDRA SISTEMAS S.A. CLASS A
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
NA9 NAGARRO
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
IFCN INFICON HOLDING AG
- Jeremy Garnier
- Jeremy Garnier
EQUASENS ANNONCE SON AGENDA FINANCIER 2026
EQUASENS ANNONCE SON AGENDA FINANCIER 2026 Villers-lès-Nancy, 10 décembre 2026, 18h00 CET – Equasens (isin : FR0012882389 – Mnémo : EQS), leader des solutions numériques pour les professionnels de santé, annonce son agenda financier pour l’exercice 2026. ÉvénementsDatesChiffre d’affaires annuel 20255 février 2026 (après bourse)Résultats annuels 202530 mars 2026 (avant bourse)Chiffre d’affaires du 1er trimestre 202629 avril 2026 (après bourse)Assemblée Générale Annuelle25 juin 2026Chiffre d’affaires du 1er semestre 202630 juillet 2026 (après bourse)Résultats du 1er semestre 202628 septembre ...
EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR
EQUASENS ANNOUNCES ITS 2026 FINANCIAL CALENDAR Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year. EventsDates2025 annual revenueFebruary 5, 2026 (after market close)2025 annual resultsMarch 30, 2026 (before market opens)2026 Q1 revenueApril 29, 2026 (after market close)Annual General MeetingJune 25, 20262026 Half-year revenueJuly 30, 2026 (after market close)2026 Half-year resultsSeptember 28, 2026 (before market opens)202...
- Maissa Keskes
- Stephane Houri
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
Pharming Group NV: 1 director
A director at Pharming Group NV sold 90,691 shares at 1.500EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
- Adrian Pehl
- Marc Lavaud
FII LISI SA
VOE VOESTALPINE AG
SDF K+S AG
INH INDUS HOLDING AG
PAL PALFINGER AG
SEM SEMPERIT HOLDING AG
ADN1 ADESSO AG
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
POST OSTERREICHISCHE POST AG
TWEKA TKH GROUP N.V. CERT
CSM CORBION NV
FACC FACC AG
JUN3 JUNGHEINRICH AG PREF
JEN JENOPTIK AG
KTA KNAUS TABBERT
SFQ SAF-HOLLAND SE
VT5 VT5 ACQUISITION COMPANY AG
SPG SPRINGER NATURE AG & CO. KGAA
CAN CANAL+
- Adrian Pehl
- Marc Lavaud
FII LISI SA
VOE VOESTALPINE AG
SDF K+S AG
INH INDUS HOLDING AG
PAL PALFINGER AG
SEM SEMPERIT HOLDING AG
ADN1 ADESSO AG
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
POST OSTERREICHISCHE POST AG
TWEKA TKH GROUP N.V. CERT
CSM CORBION NV
FACC FACC AG
JUN3 JUNGHEINRICH AG PREF
JEN JENOPTIK AG
KTA KNAUS TABBERT
SFQ SAF-HOLLAND SE
VT5 VT5 ACQUISITION COMPANY AG
SPG SPRINGER NATURE AG & CO. KGAA
CAN CANAL+
- Aurelien Sivignon
Equasens : e-health pure player with modest valuation
Equasens provides IT solutions and software for the healthcare industry. Historically positioned in the pharmacy segment (market leader in France, >40% market share), its global expansion (Italy, Germany) and business diversification (nursing homes, hospitals, private practitioners, etc.), should facilitate the return to a dynamic growth trajectory (2025-28 CAGR estimated at +7%) after two challenging years. Given the necessary investments (R&D, salesforce), we believe 2025 will mark a low for m...
- Aurelien Sivignon
Equasens : Un pure player de l’e-santé à la valorisation modeste
Equasens est spécialisé dans l’édition de solutions informatiques et logiciels de santé. Historiquement positionné sur les pharmacies (leader en France, >40% PdM), son expansion à l’international (Italie, Allemagne) et la diversification de ses activités (EHPAD, hôpitaux, libéraux, etc.) devraient faciliter le retour à une trajectoire de croissance dynamique (TMVA 2025-28e +7%), après deux exercices challenging. Au regard des investissements nécessaires (R&D, commerciaux), nous estimons que 2025...
Pharming Group reports third quarter 2025 financial results with signi...
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for c...
- Arnaud Riverain
Equasens: Q3 2025 revenue
Equasens: Q3 2025 revenue Villers-lès-Nancy, 5 November 2025 - 6:00 PM (CET) PRESS RELEASE Revenue at 30 September 2025: €172.2m+8.9% on a reported basis and +7.3% like-for-like Group revenue at 09/30/2025 (€m)2024Reported basis 2025Reported basisChange /Reported basisof which external growthLike-for-like change(organic growth)Q153.357.03.76.9%0.53.25.9%Q254.758.94.37.8%0.53.86.9%Q3*50.256.26.112.1%1.44.79.4%Total158.2172.214.08.9%2.411.67.3% * Unaudited At September 30, 2025, the (Euronext Paris™ - Compartment B - FR 0012882389 -EQS), a leading provider of digital solutions for health...
EQUASENS : Chiffre d'affaires au 30 septembre 2025
EQUASENS : Chiffre d'affaires au 30 septembre 2025 Villers-lès-Nancy, le 5 novembre 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 30 septembre 2025 à 172,2 M€+8,9% en croissance publiée et + 7,3% en croissance organique CA au 30/09/2025 Groupe (M€)Publié 2024Publié 2025Variation /publiéDont croissances externesVariation /périmètre comparable (croissance organique)T153,357,03,76,9%0,53,25,9%T254,758,94,37,8%0,53,86,9%T3*50,256,26,112,1%1,44,79,4%Total158,2172,214,08,9%2,411,67,3% *non audité Au 30 septembre 2025, le (Euronext Paris™ - Compartiment B - FR 0012882389 –EQS)...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific...
Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibi...
Pharming Group provides update on previously announced G&A expense red...
Pharming Group provides update on previously announced G&A expense reduction plan Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-com...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.